Sulopenem etzadroxil
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2024
- First approval year
- 2024
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Sulopenem etzadroxil
- Molecular weight
- 477.63
- Structure (SMILES)
- CCC(CC)C(=O)OCOC(=O)C1=C(S[C@H]2CC[S+]([O-])C2)S[C@@H]2[C@@H]([C@@H](C)O)C(=O)N12
- sulopenem etzadroxil component of orlynvah
- Sulopenem etzadroxil component of orlynvah
- 4 thia 1 azabicyclo 3 2 0 hept 2 ene 2 carboxylic acid 6 1r 1 hydroxyethyl 7 oxo 3 1r 3s tetrahydro 1 oxido 3 thienyl thio 2 ethyl 1 oxobutoxy methyl ester 5r 6s
- 4-THIA-1-AZABICYCLO(3.2.0)HEPT-2-ENE-2-CARBOXYLIC ACID, 6-((1R)-1-HYDROXYETHYL)-7-OXO-3-(((1R,3S)-TETRAHYDRO-1-OXIDO-3-THIENYL)THIO)-, (2-ETHYL-1-OXOBUTOXY)METHYL ESTER, (5R,6S)-
- methylene 2 ethylbutanoate 5r 6s 6 1r 1 hydroxyethyl 7 oxo 3 1r 3s 1 oxotetrahydro 1h 1 lamba sup 4 thiophen 3 yl sulfanyl 4 thia 1 azabicyclo 3 2 0 hept 2 ene 2 carboxylate
- METHYLENE 2-ETHYLBUTANOATE (5R,6S)-6-((1R)-1-HYDROXYETHYL)-7-OXO-3-(((1R,3S)-1-OXOTETRAHYDRO-1H-1.LAMBA.(SUP 4)-THIOPHEN-3-YL)SULFANYL)-4-THIA-1-AZABICYCLO(3.2.0)HEPT-2-ENE-2-CARBOXYLATE
- orlynvah component sulopenem etzadroxil
- ORLYNVAH COMPONENT SULOPENEM ETZADROXIL
- pf 03709270
- PF-03709270
- pf03709270
- PF03709270
- sulopenem and pf 03709270
- sulopenem etzadroxil
- Sulopenem etzadroxil
- SULOPENEM ETZADROXIL [USAN]
- Sulopenem etzadroxil [WHO-DD]
- sulopenem etzadroxil usan
- sulopenem etzadroxil who dd
- CAS registry numbers
- 1000296-70-7
- ChEMBL ID
- CHEMBL4594246
- InChIKey
- NBPVNGWRLGHULH-JKOUTOBWSA-N
- RxNorm IDs (RxCUI)
- 2717834
- FDA ingredient codes (UNII)
- 492M3I304T
- 23642298
- 49785800
- Applicant
- ITERUM THERAP
- Approval date
- 25 Oct 2024
- Application number
- NDA213972
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- Pharmacology name
- sulopenem
- Type
- Synthetic organic
- Drug name stem
- -penem
Administration routes
- Oral
- Mechanism
- Bacterial penicillin-binding protein inhibitor
- Action type
- Inhibitor
- Target
- Bacterial penicillin-binding protein
- Protein identifier
- P02918
- Mechanism
- Bacterial penicillin-binding protein inhibitor
- Action type
- Inhibitor
- Target
- Bacterial penicillin-binding protein
- Protein identifier
- P02919
- Mechanism
- Bacterial penicillin-binding protein inhibitor
- Action type
- Inhibitor
- Target
- Bacterial penicillin-binding protein
- Protein identifier
- P08506
- Mechanism
- Bacterial penicillin-binding protein inhibitor
- Action type
- Inhibitor
- Target
- Bacterial penicillin-binding protein
- Protein identifier
- P0AD65
- Mechanism
- Bacterial penicillin-binding protein inhibitor
- Action type
- Inhibitor
- Target
- Bacterial penicillin-binding protein
- Protein identifier
- P0AD68
- Mechanism
- Bacterial penicillin-binding protein inhibitor
- Action type
- Inhibitor
- Target
- Bacterial penicillin-binding protein
- Protein identifier
- P0AEB2
- Mechanism
- Bacterial penicillin-binding protein inhibitor
- Action type
- Inhibitor
- Target
- Bacterial penicillin-binding protein
- Protein identifier
- P24228
Open Targets mechanisms
- Mechanism
- Bacterial penicillin-binding protein inhibitor
- Action type
- Inhibitor
- Target
- Bacterial penicillin-binding protein
- Condition
- Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Urinary Tract Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003103
- Subject identifier
- D014552
- Condition
- Pneumonia
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003106
- Subject identifier
- D011014
- Condition
- Cystitis, Hemorrhagic
- Highest recorded phase
- 3
- Condition identifier
- EFO:1000025
- Subject identifier
- D000096722
- Condition identifier
- EFO_0000771
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003103
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003106
- Highest recorded phase
- 1
- Condition identifier
- EFO_1000025
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0003529
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005113
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006939
- Highest recorded phase
- 3
- NCT00759564
- NCT03354598
- NCT03357614
- NCT05584657
- NCT03358576
- Dose
- 500 mg sulopenem etzadroxil and 500 mg probenecid
- Route
- Oral
- How often
- Twice daily
Conditions of use
- Take with food
- Hydrogen bond acceptors
- 9
- Hydrogen bond donors
- 1
- Polar surface area
- 116.2
- Calculated partition coefficient (ALogP)
- 1.8
- Calculated partition coefficient (XLogP)
- 2.1
- Prodrug
- Yes
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 9
- Heavy atoms
- 30
- Molecular formula
- C19H27NO7S3
- Monoisotopic mass
- 477.09496572
- Natural product
- Yes
- 81153-100
Related records
Trials (8)
- A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization
- A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function
- Expanded Access Use of Sulopenem Etzadroxil/Probenecid for Complicated Urinary Tract Infection
- Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women
- Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women
- Pharmacokinetics of Sulopenem Etzadroxil Plus Probenecid in Adolescents
- Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults
- Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)
In development for (4)
- Bacterial infectious disease Phase 2
- Cystitis Phase 3
- Pneumonia Phase 1
- Urinary tract infection Phase 3